iSonea raises $13.5m to fund AirSonea launch
iSonea (ASX:ISN) has completed a $13.5 million placement to help raise funds for the market launch of its AirSonea mobile wheeze-monitoring device.
The company placed 38.6 million shares with clients of Patersons Securities at $0.35 per share. The allocation represents around 17.5% of the company’s share capital.
iSonea CEO Michael Thomas said the additional cash will be used to fund the Australian launch of AirSonea later this year and its debut in the US in early 2014.
“This key fundraising enables [us] to focus on ensuring the AirSonea product commercialisation is properly funded across every aspect of the launch, from product manufacturing and distribution channel management, right through to ... marketing and sales,” he said.
The company last month selected a manufacturing partner for the device. Hong Kong-based Refined Manufacturing, which produced several prototype AirSonea units, has secured the contract.
iSonea has also been conducting market research in the lead-up to the Australian launch.
iSonea shares were trading 2.04% lower at $0.48 as of around 12.30 pm on Tuesday.
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
Global study finds 250 genes linked to OCD
Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...
TGA approves therapy for paediatric growth hormone deficiency
The TGA has approved SKYTROFA as a treatment for growth failure in children and adolescents aged...
